By Greg Ryan ( June 5, 2013, 5:06 PM EDT) -- A U.S. Food and Drug Administration official on Wednesday blasted a Duke University research group's re-examination of a GlaxoSmithKline PLC trial for the former blockbuster diabetes treatment Avandia, charging that the group's ties to the drugmaker compromised its analysis....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.